Related Experiment Videos

Apoptosis in HIV infection: protective role of IL-2

P Cordiali Fei1, M Solmone, M Viora

  • 1Laboratory of Clinical Pathology, Istituto San Gallicano, Roma, Italy.

Insights

Peripheral blood mononuclear cells (PBMC) from HIV patients undergo apoptosis, increasing with disease severity. Interleukin-2 (IL-2) addition significantly reduced this apoptosis in HIV-infected individuals.

Area of Science:

  • Immunology
  • Virology
  • Cell Biology

Background:

  • Peripheral blood mononuclear cells (PBMC) from individuals with Human Immunodeficiency Virus (HIV) infection are prone to apoptosis in vitro.
  • Apoptosis, or programmed cell death, is a critical factor in immune dysfunction during HIV pathogenesis.

Purpose of the Study:

  • To quantify apoptosis in PBMC from HIV-infected individuals across different disease stages.
  • To investigate the correlation between apoptosis, clinical staging, and CD4/CD8 ratio in HIV infection.
  • To evaluate the effect of Interleukin-2 (IL-2) on PBMC apoptosis in HIV patients.

Main Methods:

  • PBMC were isolated from healthy controls and HIV-infected subjects (asymptomatic and advanced disease).
  • Apoptosis was measured using propidium iodide staining and flow cytometry.
  • Statistical analysis was performed to correlate apoptosis with clinical stage (CDC classification) and CD4/CD8 T cell ratio.

Main Results:

  • Apoptosis percentages in PBMC significantly increased with HIV disease progression (CDC II vs. CDC IV, P < 0.001).
  • A significant negative correlation was observed between PBMC apoptosis and the CD4/CD8 T cell ratio (R = -0.57, P = 0.012).
  • No significant difference in apoptosis was found related to AZT therapy, but IL-2 addition markedly reduced PBMC apoptosis in HIV-infected patients.

Conclusions:

  • PBMC apoptosis is a key feature of HIV infection, directly linked to disease severity and immune cell imbalance.
  • Interleukin-2 demonstrates a potent anti-apoptotic effect on PBMC in the context of HIV infection.
  • These findings suggest IL-2 as a potential therapeutic agent to mitigate immune cell loss in HIV/AIDS.

Related Concept Videos